Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US
Despite incorporating PD-(L)1-based therapies for frontline mNSCLC, mortality and attrition during LOT1 remained high and therapy duration was short, reflecting challenges in managing mNSCLC.
Authors
- Adam J. Schoenfeld (ORCID: https://orcid.org/0000-0002-2644-1416)
- Iftekhar Kalsekar (ORCID: https://orcid.org/0000-0001-5232-5972)
- Chen Hu (ORCID: https://orcid.org/0000-0003-4672-1981)
- Akhmad Endang Zainal Hasan (ORCID: https://orcid.org/0000-0002-3916-1544)
- Tianyi Wang (ORCID: https://orcid.org/0000-0002-5671-7321)
- Charlene Wong (ORCID: https://orcid.org/0000-0001-9209-1517)
- Josephine Feliciano (ORCID: https://orcid.org/0009-0008-8163-2304)
- Qing Huang (ORCID: https://orcid.org/0000-0001-6441-7591)
- Ravi Rajaram (ORCID: https://orcid.org/0000-0003-2782-7756)
- Urmila Chandran (ORCID: https://orcid.org/0000-0001-7183-3622)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Cornell University (US)
- Johns Hopkins Medicine (US)
- Johnson & Johnson (Israel) (IL)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1080/14796694.2025.2592721
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00